BioNTech (NASDAQ:BNTX) Given New $131.00 Price Target at UBS Group

BioNTech (NASDAQ:BNTX) had its price objective upped by UBS Group from $97.00 to $131.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts have also issued research reports about the stock. TD Cowen decreased their price objective on shares of BioNTech from $98.00 to $85.00 and set a hold rating for the company in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a buy rating and set a $113.00 price target on shares of BioNTech in a research report on Monday. HSBC raised BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the company a buy rating in a research report on Monday. Finally, Jefferies Financial Group raised shares of BioNTech from a hold rating to a buy rating and boosted their price target for the stock from $96.00 to $150.00 in a report on Tuesday. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $120.31.

BioNTech Stock Down 7.3 %

BNTX stock opened at $115.62 on Wednesday. The firm has a market capitalization of $27.49 billion, a PE ratio of 231.24 and a beta of 0.23. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The stock’s 50 day moving average is $89.02 and its 200-day moving average is $90.14.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same quarter last year, the business posted ($0.86) earnings per share. BioNTech’s revenue was down 23.3% on a year-over-year basis. Sell-side analysts expect that BioNTech will post -2.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Harding Loevner LP bought a new position in shares of BioNTech in the fourth quarter worth $410,984,000. Candriam S.C.A. boosted its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. grew its holdings in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after buying an additional 131,490 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of BioNTech by 610.5% in the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after acquiring an additional 60,270 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.